LNB
GEVA

Ledyard National Bank’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Ledyard National Bank’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-30
Closed -$2K – 748
2014
Q3 		$2K Hold
30
– – ﹤0.01% 688
2014
Q2 		$3K Hold
30
– – ﹤0.01% 677
2014
Q1 		$2K Hold
30
– – ﹤0.01% 689
2013
Q4 		$2K Buy
+30
New +$1.78K ﹤0.01% 700

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Ledyard National Bank's GEVA Position: Q4 2014 in Review

Ledyard National Bank sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q4 2014, closing a stake of 30 shares — an estimated $2K sold.

Ledyard National Bank first reported a position in GEVA in Q4 2013 and held it in 4 quarters. The position peaked at $3K in Q2 2014. 126 funds tracked by Wall St. Rank hold GEVA as of Q4 2014.

  • Ledyard National Bank reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q4 2014 after selling out during the quarter.
  • Ledyard National Bank sold 30 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q4 2014, an estimated $2K.
  • Ledyard National Bank first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q4 2013 and held it in 4 quarters.
  • Ledyard National Bank's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $3K in Q2 2014.
  • 126 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q4 2014.

Based on Ledyard National Bank's 13F filing for Q4 2014, filed 16 Jan 2015.